CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Businesses  /  Generics  /  Pipeline

GENERIC FORMULATIONS

Pipeline

The pipeline comprises oral solids and parenteral formulations in both the potent and non-potent compounds categories, in the core therapeutic areas of metabolics, cardiovascular, oncology and immunotherapy.

Our products

Tacrolimus
Commercialized in
United States

Rosuvastatin
Commercialized in
United States & EU

Simvastatin
Commercialized in
United States

Atorvastatin
Commercialized in
United States

Pravastatin
Commercialized in
United States

Everolimus
Commercialized in
U.S. & Approved in EU

Fingolimod
Approved in
United States & EU

Pemetrexed
Tentative Approval
(United States)

Dapagliflozin
Tentative Approval
(United States)

Labetalol
Commercialized In
United States

Esomeprazole
Commercialized In
United States

Posaconazole
Commercialized in
United States

Filings

To support our filings, we commissioned our first oral solid dosage facility in Bengaluru. The facility successfully completed several regulatory audits subsequently following our various filings in the U.S. and Europe. We have built commercial infrastructure to support this initiative in the U.S.

For more information on FORMULATIONS, please send your enquiry to: contactus.formulations@biocon.com

Siddharth Mittal
KEY MANAGEMENT TEAM
PRODUCTS
PRESS RELEASES
CORPORATE GOVERNANCE
R&D
WORKING WITH US
Share